Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Covalent Modification: Chemical Biology and Therapeutic Applications

WEBINAR

Only

Covalent Modification: Chemical Biology and Therapeutic Applications

Tuesday, November 9, 2021, 10:00 AM - 5:00 PM EST

Webinar

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Covalent target modulation is reemerging as a promising strategy to identify novel therapeutic mechanisms and to drug “tough” targets. Technological advance in proteomics have opened the door to a wider range of targetable residues and set the stage for rational design of covalent modifiers.  For example, the development of the KRAS G12C covalent inhibitor has heralded a new paradigm for these agents. This symposium will convene a diverse group of academic and industry scientists from the fields of medicinal chemistry, chemical biology, proteomics and pharmacology to discuss the latest research in the design of covalent libraries and new warheads, addressing intrinsic reactivity of ligands and their relationship to promiscuousness, deconvolution of hits emerging from phenotypic screens, warhead PK tolerance and identification of novel targets in human disease context to name a few. This symposium will empower attendees to think boldly about covalent inhibitors for intractable targets and build confidence in initiating successful covalent screening campaigns, further the ground-breaking work of the speakers and gain confidence in clinical translation of covalent molecules.

Call for Abstracts

You are invited to submit a poster abstract which will be displayed virtually on our website. See here for submission guidelines. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Friday, September 3, 2021.

Keynote Speaker

Kevan Shokat, PhD

University of California, San Francisco

Speakers

Keriann Backus, PhD

University of California, Los Angeles

Nir London, PhD

Weizmann Institute of Science

Lynn McGregor, PhD

Novartis Institutes for Biochemical Research

Gabriel Simon, PhD

Vividion Therapeutics

Ingrid Wertz, MD, PhD

Genentech

Scientific Organizing Committee

Chris Am Ende, PhD

Pfizer

Ku-Lung (Ken) Hsu, PhD

University of Virginia

Jaimeen Majmudar, PhD

Pfizer

Uthpala Seneviratne, PhD

Pfizer

Monica Schenone, PhD

Pfizer

Eranthie Weerapana, PhD

Boston College

Program Supporters